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ABSTRACT 
Waterproofing agents are widely used to protect leather and textiles in both domestic and occupational 
activities. An outbreak of acute respiratory syndrome following exposure to waterproofing sprays occurred 
during the winter 2002-2003 in Switzerland. About 180 cases were reported by the Swiss Toxicological 
Information Centre between October 2002 and March 2003, whereas less than 10 cases per year had been 
recorded previously. The reported cases involved 3 brands of sprays containing a common waterproofing 
mixture, which underwent a formulation change in the months preceding the outbreak.  
A retrospective analysis was undertaken in collaboration with the Swiss Toxicological Information Centre 
and the Swiss Registries for Interstitial and Orphan Lung Diseases to clarify the circumstances and possible 
causes of the observed health effects. Individual exposure data was generated with questionnaires and 
experimental emission measurements. The collected data was used to conduct numeric simulation for 102 
cases of exposure. A classical two-zone model was used to assess the aerosol dispersion in the near and far-
field during spraying. The resulting assessed dose and exposure levels obtained were spread on large scales, 
of several orders of magnitude. No dose-response relationship was found between exposure indicators and 
health effect indicators (perceived severity and clinical indicators). Weak relationships were found between 
unspecific inflammatory response indicators (Leukocytes, C-reactive protein) and the maximal exposure 
concentration. The results obtained disclose a high inter-individual response variability, and suggest that 
some indirect mechanism(s) predominates in the respiratory disease occurrence. Furthermore, no threshold 
could be found to define a safe level of exposure. These findings suggest that the improvement of 
environmental exposure conditions during spraying alone does not constitute a sufficient measure to 
prevent future outbreaks of waterproofing spray toxicity. More efficient preventive measures are needed 
prior to the marketing and distribution of new waterproofing agents.  
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INTRODUCTION 
 
Fluorinated polymers are widely used in a number of technologies requiring low surface energy, such as 
coating surface applications. The high electronegativity of fluorine strongly affects the molecules physical 
and chemical properties (1). Amongst other effects, the presence of fluorine tends to reduce surface tension 
and enhance thermal and chemical stability. Fluoro-acrylate polymers, which exhibit a high stability and 
durability, are increasingly used in coating. Diluted into solvents of low polarity, the polymers may be used 
to coat various surfaces either in liquid or aerosol application (spraying).   
There is strong evidence that inhalation of waterproofing spray can lead, in certain circumstances, to 
respiratory disorders. Outbreaks of respiratory failure following the use of waterproofing sprays occurred in 
Germany between 1979 and 1983 (2,3), and in the United States, Canada and Japan in 1992-1993 (4,5,6). A 
recent case was also reported in Japan (7). Each outbreak closely followed the marketing of a product, which 
underwent a formulation change of the solvent (to eliminate ozone-depleting solvents) and the fluorinated 
polymer (to increase solubility in the new solvent). Clinical and experimental findings of previous studies 
suggest that the reformulation of the products may have played a central role in pathogenesis because of the 
direct pulmonary toxicity of the new fluorinated resins or a possible increase in the amount of respirable 
fluororesin particles emitted (8,9). Short-term management of previous outbreaks was mainly based on the 
removal of incriminated products from the market, but this strategy did not prevent new outbreaks to occur 
later with similar waterproofing agents. Instead, the periodical recurrence of toxicity outbreaks suggests 
that safety issues in the development of coating mixtures have so far followed a trial-and-error process, 
rather than a long-term anticipatory and preventive strategy. 
A new outbreak of respiratory illness due to waterproofing sprays occurred recently in Switzerland (10, 11). 
More than 180 cases were reported between October 2002 and March 2003, whereas 10 cases per year had 
been observed in the previous years. Although various commercial products were involved, they had a 
common waterproofing agent: a mixture of fluorinated polymer and isoparaffinic hydrocarbons, which 
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underwent a formulation change in both solvent and polymer shortly prior to the outbreak. Unlike the 
former one, the new polymer is a fluoro-acrylate polymer. The same waterproofing agent appeared to be 
involved in a simultaneous outbreak reported in the Netherlands (12) and in a fatal case reported from France 
(13). A fatal case occurred also in the UK (14) at about the same period and under similar conditions.  
Most of the incidents observed in Switzerland occurred after domestic activities, following the application 
of leather and textile waterproofing sprays. Three occupational cases following the use of a stain-repellent 
resin on stone-tiled walls and floors were also reported (15). The exposure conditions of these three cases 
were investigated in a previous study (16). Emission measurements and simulations indicated that: (1) 
significant aerosol and solvent concentrations may occur during waterproofing, and that (2) the amounts of 
solvent and particles in the workers’ breathing zone were lower with the new resin formulation. This last 
result strongly suggests that the respiratory illness is related to the fluorinated polymer itself rather than to 
an increase of the exposure level to solvents and particles.  
The toxic mechanism involved is unclear and several hypotheses can be suggested. On the one hand, a 
direct mechanism may be hypothesised. The polymer particles may exert their waterproofing effect on the 
alveolar surface, thereby increasing alveolar surface tension, counteracting the effect of surfactant, and 
leading to alveolar collapse and impairment in gas exchange as previously suggested (17). This hypothesis is 
somehow supported by the polymer stability and the absence of a polymerisation reaction during the 
formation of the coating layer (evaporation only). On the other hand, an indirect mechanism requiring a 
metabolic activation with or without interaction with other factors (i.e solvents, smoking) may also take 
place. Previous examples of such interactions have been reported in the case of polytetrafluoroethylene 
(e.g. Teflon) for instance (18). 
Although the commercial products involved in the Swiss outbreak have been withdrawn from the market, 
waterproofing agents remain widely used. Moreover, new polymers and product formulations are regularly 
developed and marketed. The periodical recurrence of respiratory disease observed with these products is 
therefore a long-term concern for both public and occupational health. Understanding the conditions under 
which the illness occurs is of high interest to better prevent and control future outbreaks.  
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The Institute of Occupational Health Sciences (IST), the Swiss Toxicological Information Centre and the 
Swiss Registries for Interstitial and Orphan Lung Diseases1 undertook a joint study of the 2003 Swiss 
outbreak. Exposure conditions and health effects were investigated in a retrospective way through 
questionnaires, emission measurements and numeric simulation. The main objectives were to characterise 
the exposure conditions during spraying and the possible relationship between exposure and observed 
health effects, in order to clarify the causes of the outbreak and formulate preventive recommendations.  
 
METHODS 
Questionnaires   
Following a small cluster of cases of waterproofing spray toxicity observed in one hospital, the Swiss 
Registries for interstitial and orphan lung diseases network (SIOLD) and the Swiss Toxicological 
Information Centre (STIC) were alerted and a search for other cases was initiated through national medical 
societies and a Swiss medical journal. The reported cases were systematically investigated through 
questionnaires. Each individual involved received a questionnaire covering the exposure conditions and the 
perceived intensity of the respiratory reaction (patient’s questionnaire)2. The questionnaire asked for the 
type of waterproofing agent used (commercial name), the spraying activity (approximate spraying time, 
approximate amount of product used, items sprayed), the exposure environment (exposure location, room 
dimensions, open windows and doors, time spent in the same room after spraying) and perceived health 
effects (symptoms, time before occurrence, time before medical care, symptoms duration). Additional 
                                                 
1 The term “orphan diseases” is used to describe >6000 disorders characterized by a very low prevalence 
(<1/1000 in the USA) but a severe health impairment or a threat to life. The rarity of a disorder greatly 
impairs all processes of disease control, such as the physician’s skill to manage the disorder, scientific 
advances and drug availability. 
2 The questionnaire, written in French and German, is not detailed in this paper. The corresponding author 
may provide it upon request. 
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questions regarding potential contributing or confounding factors, such as smoking habits, were also 
included in the questionnaire.  
Data on the clinical findings was collected from patients who underwent medical examination and 
diagnostic procedures. Patients were asked to send the medical documents in their possession (laboratory 
results reports, chest X-ray), and questionnaires were sent to their physicians (physician’s questionnaire). 
Common clinical parameters were extracted from these questionnaires and documents. They included 
severity parameters on admission (dyspnoea levels, respiratory rate, symptoms observed, need for 
supplemental oxygen) as well as objective clinical parameters (C-reactive protein, white blood cells (WBC) 
and arterial PO2 levels). These clinical parameters, when available, were used as severity indicators of 
health effects. The clinical features of the pulmonary toxicity syndrome as well as the control of the 
outbreak by Public Health authorities will be described in detail in forthcoming papers.  
 
Three subjective indicators of exposure effects have been considered in this study: the delay before medical 
care (DELAY), the perceived symptoms (SCORE) and the dyspnoea score (DYSP). The delay before 
medical care depends strongly on the severity of the perceived effects from the patient's point of view. The 
more serious the patient believes the situation is, the more likely it is he will ask for urgent medical 
assistance. The symptoms reported by the patients were categorized according to the affected system: 
general (fever, shivers or myalgias), respiratory (cough or dyspnea), neurologic (giddiness, headache, or 
loss of consciousness), digestive (nausea, vomiting or abdominal pain) and Eyes/Ear-Nose-Throat (ENT) 
(burning eyes or throat). An arbitrary index of disease severity was used, one point was attributed to each 
affected system (i.e. a system for which one or more symptoms were present) and the number of systems 
affected was added to produce a symptom score (SCORE). Thus, a score of one indicates that symptoms 
were reported in only one system, while a score of five indicates that symptoms were present in all systems. 
The New York Heart Association dyspnoea score is a widely used medical rating of the severity of dyspnea 
ranging from I (shortness of breath on heavy exertion) to IV (shortness of breath at rest). The DYSP value 
used in this study is the dyspnoea score established during the first medical examination.  
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Emission rate during spraying 
The amount of respirable particles emitted during spraying must be known in order to assess aerosol 
exposure. An estimate based on a theoretical approach is quite complex in the case of volatile aerosol 
emissions because key parameters, such as the diameter of droplets and their velocity, become time 
dependent. Moreover, the initial size distribution of the particles is strongly dependent on the physico-
chemical properties of the product and the discharge conditions (pressure, nozzle size). Because of this, the 
use of theoretical models, such as the one proposed by Flynn(19) to predict transfer efficiency from 
compressed air spray guns during painting, is limited in this case. The spray cans used in our study may 
indeed differ significantly from air spray guns.  
 
Figure 1 about here 
 
An experimental approach, based on the measurement of the overspray, was therefore used. The 
experiment was similar to the one used to assess the transfer efficiency of the nebulizer-spray proposed by 
Tan and Flynn. (20). The spraying was performed in a 7.9 m3 experimental chamber with a constant 
descending laminar airflow (Figure 1). The air renewal of the experimental chamber reached a 9.7 air 
change per hour. During the spraying, the large particles impacted on the ground surface while the smaller 
particles, constituting the overspray mist, escaped through the perforated floor plate. Overspray aerosol 
concentrations C(t) were measured in the exhaust duct at a downstream distance of about 5 meters. It was 
assumed that, at this point, the volatile compounds of the particles had evaporated during the transport 
process (16). Aerosol concentrations and distribution were measured with a light-scattering device: a Grimm 
Dust Monitor (model 1.102, Labortechnik GmbH, Ainring, Germany). 
The experimental chamber was separated from the laboratory by airtight doors, and a slight depression (10 
Pa) was maintained in it to avoid any leakage during the experiment. An airtight glove system allowed the 
experimenter to use the spray from outside. As shown in Figure 2, the spray was introduced into the 
chamber using repetitive short emission pulses. This “discontinuous emission” procedure was intended to 
avoid a significant temperature drop of the spray cans, which decreases the emission rate. It is also 
  page 6/37 
   
considered advantageous because it lengthens the possible duration of the experiment per spray can. As 
shown in Figure 2, the instantaneous emission rate Ei [mg/s] may easily be deduced from the cycle time (t1) 
and emission time (t2): E
t
tEi 
2
1  (Equation 1). 
 
Figure 2 about here 
 
 
As very few of the original cans were available, preliminary experiments were therefore performed with 
commercial waterproofing sprays currently available on the market. These tests aimed to define the 
measurement protocol and set up the experimental parameters. A 5 seconds cycle time (t1) was chosen. 
Each 5 seconds, a short spray pulse was emitted into the chamber. The experiment was recorded on a 
digital camera (DCR-TRV7E, Sony Corporation, Japan) and analysed in slow motion replay. The average 
pulse duration obtained (emission duration, t2) was 0.42 seconds. By using these parameters, steady state 
conditions are achieved in about 10 minutes. At this point, the concentration in the exhaust duct reaches a 
constant value and the emission rate may be calculated by using a simple mass balance equation.  
  ductduct QCE   (Equation 2).  
 
The preliminary experiments were also used to validate the aerosol measurement method. Results obtained 
from the Grimm Dust Monitor were compared with those of a Personal Data Ram (PDR, global 
concentration) and of an Andersen impactor (particle distribution). The average variations for fine particles 
(<10m) were 12.6 % for the PDR and 8.9 % for the Andersen. These differences are not relevant in 
comparison with the uncertainties of other simulation parameters (such as the spraying time), which were 
established on the basis of patient’s questionnaires. Moreover, they may easily be explained by the slight 
difference in the working ranges between the measuring devices.  
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Modelling of exposure concentrations.  
As the health effects observed were essentially located at the pulmonary alveolar level (11,15), our concern 
regarding particulate matter was limited to respirable aerosols (<10 m). Due to their limited mass and size, 
fine particles are not affected significantly by the gravitation and aerodynamic forces shortly after their 
emission and thus, behave in a similar way to gases with regard to their transportation and dispersion. 
Classical gas dispersion models can therefore be used to assess the respirable aerosol concentrations in the 
breathing zone at the time of exposure.  
The well-known Two-Compartment Model (Figure 3) is used in this study (21). The choice of this 
compartmental model is based on practical considerations. On the one hand, only models based on simple 
parameters, accessible through questionnaires or literature, can be used in such retrospective study. On the 
other hand, the simplest compartmental model, the Well-Mixed Room Model, which considers a uniform 
concentration through the room, may severely underestimate the exposure near the source (22). The Two-
Compartment Model considers two ideally mixed dispersion volumes: the near-field zone (NF), containing 
the emission source including the individuals’ breathing zone, and the far-field zone (FF) representing the 
remaining part of the room. Near and far-field zones are interconnected by an inter-compartment flow (Qe), 
which ensures the air and pollutant circulation inside the room. The model used considers air renewal in 
both near and far-field, although variations due to local geometrical effects, such as the spray orientation 
can not be taken into account. The evolution of the pollutant concentration into the two compartments is 
given in the following equations: 
dt)CQCQE(dCV NFeFFeNFNF      (equation 3) 
  dt)CQQCQ(dCV FFeNFeFFFF      (equation 4) 
 
 
Figure 3 about here 
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DATA FROM QUESTIONNAIRES 
Patient’s questionnaires were returned for 105 cases (return rate 52 %). 3 of them, in which mandatory data 
was missing or inaccurate, were discarded. The exposure conditions and/or clinical data reported in the 102 
remaining cases were analysed. One could argue that some subjects may have wrongly attributed their 
symptoms to aerosol exposure, whereas the symptoms had in fact another origin, such as a viral infection. 
Although such a bias cannot be completely ruled out, we believe that the causality between aerosol 
exposure and symptoms appears extremely likely in most, if not all, cases, in view of the acute onset of 
symptoms after exposure, the clear temporal relationship between exposure and symptom occurrence, the 
absence of pre-existing diseases in most cases, the rapid improvement within days after the exposure, and 
the absence of an alternative explanation for the symptoms detected by the questionnaire. Despite the fair 
return rate of questionnaires, a lack of representativeness remains a possible bias. Individuals having 
endured only minor health effects may be less concerned and therefore less prone to fulfil the 
questionnaire.  
Products  
The products involved were mostly commercial spray cans intended for domestic or light occupational 
waterproofing activities. RapiAquaStop (Werner & Mertz GmbH, Mainz, Germany) was the most 
frequently involved spray (46% of cases). The two other sprays reported were K2R (K2R Produkte GmbH, 
Gottmadingen, Germany) and RapiIntemp (Werner & Mertz GmbH, Mainz, Germany) in respectively 27% 
and 12% of the cases. Several of these products were involved in all but three of the remaining cases. A 
combination of several products was used in the remaining cases. In two cases, the product name was not 
remembered or not known. One occupational exposure occurred with Patina-Fala (PATINA-FALA 
Beizmittel GmbH, Haar, Germany), a liquid stain-repellent mixture, when coated with a manual trigger 
spray. This specific case has already been addressed in a previous study(16). The four identified products 
underwent a formulation change in both solvents and polymer prior to the incidents. A common 
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waterproofing agent was present in all of them: a mixture of fluorinated acrylate polymer and isoparaffinic 
hydrocarbons.  
 
Exposure conditions  
Surprisingly often, the exposures took place in an outdoor environment, 14 % occurred in open-air and 32 
% in a partially open area such as a terrace or a balcony. Indoor environments were reported in 54 % of the 
cases. Ventilation (either natural or forced) was present in most of them (92%). No ventilation (no open 
door, no open window) was reported in only 8 % of the indoor cases.  
The average volume of the rooms in which spraying took place was 49 m3  (ranged between a minimum of 
5.7 m3 and a maximum of 250 m3, in the case of a garage). 80% of the exposures took place in rooms of 
less than 75 m3. The spraying times ranged from a few seconds to 90 minutes, while the residence time 
(time spent in the same room after the spraying activity) ranged from 0 to 12 hours. 80% of the exposure 
times were shorter than 20 minutes and 80% of the residence times were shorter than 25 minutes. The 
distribution of reported spraying duration and total exposure duration (spraying time + residence time) are 
shown in Figure 4. The exact duration is difficult to assess retrospectively and a significant uncertainty is to 
be expected with these two parameters. This uncertainty is however mitigated by the wide range of values 
reported, which fall within several orders of magnitude. 
 
 
Figure 4 about here 
 
Effects  
Nearly all exposed individuals reported respiratory symptoms such as cough or dyspnoea (98 % of cases). 
22% had digestive troubles, such as nausea, vomiting or abdominal pain. 37% experienced general 
symptoms like fever, shivers or myalgias. 40% had neurological troubles such as giddiness, headache or 
loss of consciousness. Eye or throat burning was reported in 20% of cases.  
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For 20 % of the exposed individuals, the symptoms were serious enough to require emergency hospital 
admission. Another 32% received ambulatory medical care, either from their regular physician or a hospital 
facility. The remaining 48% merely called the toxicological information centre, but they were not examined 
clinically. 
The medical units carried out various diagnostic procedures. Three of them, which were frequently 
performed, were of particular interest in this study (each of them was performed in about 25-30 % of the 
cases). Two non-specific markers of inflammatory response were considered: the white blood cell count 
(WBC) and the serum C-reactive protein (CRP) concentration. The arterial partial oxygen pressure (PaO2), 
reflecting pulmonary gas exchange, was also considered a marker of lung damage and impaired respiratory 
function. When diagnostic procedures were repeated several times for the same patient, the clinical value 
considered and discussed here below corresponds to the extreme observed (max for WBC and CRP, min 
for PaO2). The white blood cell count (WBC) ranged between a minimum of 6.0 G/l (109 units per litre) 
and a maximum of 26.6 G/l  with an average of 15.4 G/l (normal values 4-9 G/l). The CRP concentrations 
ranged between a minimum of 3 mg/dl and a maximum of 264 mg/dl with an average of 59 mg/dl (normal 
values <5 mg/dl). The PaO2 while breathing room air ranged between 38 and 102 mmHg, with an average 
of 66 mmHg (normal values >80 mmHg).  
47% of the involved individuals were active smokers, 25% were former smokers, and 28% had never 
smoked. Amongst the 64 cases in which a clinical assessment was available, 23% had a history of allergy, 
and 14% had a history of asthma or chronic obstructive pulmonary disease (COPD). 
 
EXPERIMENTAL DATA  
Emission rate during spraying 
The average aerosol concentrations measured were 1.77 μg/m3 for RapiAquaStop and 2.39 μg/m3 for K2R. 
Considering an exhaust flow of 0.021 m3/s (Q duct), the amount of overspray emitted (E) may easily be 
obtained using Equation 2. An instantaneous overspray emission of 0.19 mg/s and 0.25 mg/s was 
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respectively found for RapiAquaStop and K2R. A gravimetric measurement (weighting of the spraying 
cans) indicated that the fraction of overspray in the total mass of emitted product was 0.073 % for 
RapiAquaStop and 0.124 % for K2R.  
Typical particle size distribution for K2R and RapiAquaStop is shown in Figure 5 (distribution are is 
expressed here in mass fraction and not in particle count). Particle size distribution for both products is 
similar and little differences were found between the toxic products and the apparently non-toxic products 
marketed afterwards. Differences in overspray emission rates were found between toxic and non-toxic 
products, although they tend to diverge. The fraction of overspray in the emitted (non-toxic) product was 
higher for RapiAquaStop (about 0.15%) and lower for K2R (about 0.01%). No can of RapiIntemp, the third 
waterproofing spray, was available. As RapiIntemp and RapiAquaStop are comparable products delivered 
in similar cans, it was assumed that their emission characteristics were similar.   
 
 
Figure 5 about here 
 
In practice, the mean emission rate is lower than the instantaneous emission rate as the spray is not 
activated permanently. It was estimated that, during textile or leather waterproofing activities, the spray 
was activated about 50% of the time. A mean emission rate corresponding to 50% of the instantaneous 
emission measured was therefore considered in this study. A different ratio was used for 35% of the cases, 
where the reported spraying time was too high when compared to the amount of product available. When 
the spray had been obviously used less than 50% of time, the mean emission rate was adjusted according to 
a simple mass balance relationship (mean emission rate = amount of product used . percentage of overspray 
/ reported spraying time).  
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MODEL IMPLEMENTATION  
The dispersions were modelled through numerical simulations using Ithink (version 7.0.2, HPS High 
Performance Systems, Inc., Hanover, NH). The spray emission rates measured experimentally were 
introduced into the two-zone model. The spraying conditions described in the questionnaires were used to 
set the various parameters required in the two-zone model. The room volume, spraying time and residence 
time were depicted by quantitative parameters in the questionnaires and could therefore be used as such in 
the numeric simulation. Parameters related to the ventilation conditions (air renewal) and inter-
compartment exchanges were assessed on the basis of qualitative information about the number of openings 
in the room (windows or doors) and their connected spaces (outdoor connection or connection with another 
room)(23). The conditions reported were categorized in a reduced number of ventilation scenarios following 
the rules given in Table 1.  
 
(Table 1 about here ) 
 
 
Two exposure times were considered to assess the breathed dose. The spraying time, during which the 
person was exposed to a near-field concentration, and the residence time, during which the exposure level 
was of a far-field concentration. A typical example of concentration and dose profile obtained from 
simulation is presented in Figure 6. In the case of outdoor exposures, the far-field volume was considered 
as infinite and the exposure during residence time was negligible.  
 
Figure 6 about here 
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RESULTS AND DISCUSSION 
 
Exposure assessment 
An overview of the results obtained using the two-zone model are shown in Figure 7. The maximal 
concentrations assessed ranges from 0.003 mg/m3 to 35.98 mg/m3 (mean value 4.21 mg/m3) while the 
estimated doses range from 0.2.10-5 mg to 11.27 mg (mean value 0.657 mg). The two distributions are of 
approximately lognormal shapes. In a general sense, both assessed doses and concentrations exhibit wide 
ranges of values. The array of values is particularly large for the estimated dose, where seven orders of 
magnitude separate the upper and lower limits. This scattering mostly results from the variety of spraying 
and residence times reported in the questionnaires. 
 
Figure 7 about here 
 
Because of the trivial exposure model considered and the conservative assumptions made, only a limited 
confidence should be given to the absolute numbers. Still, their relative ranking is of utmost interest. The 
exposure levels obtained indicate that the respirable mists from the waterproofing sprays have a very low 
NOEL (No Observable Effect Level). Adverse effects may obviously occur even at exposure or dose levels 
corresponding to well ventilated spaces, or very short exposure times. Considering the products involved 
are widely marketed and only a small fraction of users reported troubles, these results suggest that a high 
response variability exists between exposed individuals.  
This variability may be caused by individual factors amongst the spray users such as physiological, or 
metabolic differences. It should also be noted that the reported effects are presumably not of allergic nature. 
Another cause of variability is the presence of external factors related to exposure conditions. A typical 
example of this is the case of exposure to Teflon fumes (24), where the presence of the toxic product is 
triggered by a heat source. However, in this study, no heat source in the vicinity of the spraying activity 
was reported and smoking during or shortly after spraying was reported in only 10 out of the 102 cases. 
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Exposure vs. perceived effects 
Subjective indicators of exposure effects were compared to exposure levels for possible correlations. These 
comparisons are summarized in Table 2. No significant relationship was found with the dose or the 
maximal concentration obtained during the retrospective assessment. These results suggest that factors 
other than exposure to overspray mist play a determining role in the occurrence of adverse health effects. 
The relationship between the parameters of basic exposure conditions (amount of product, spraying time) 
and the perceived effects are poor. A statistically significant correlation was found between the perceived 
symptoms (SCORE) and these parameters, although calculation of the regression coefficients (0.017 for 
spraying time and 0.001 for amount of product) indicated that the contribution of exposure conditions on 
symptoms occurrence was limited. Besides, the perceived effect indicators should be considered carefully 
because they rely heavily on subjective perception. 
 
Table 2 about here  
 
 
Exposure vs. objective clinical effects    
The objective clinical indicators collected in the physician’s questionnaires were compared to the assessed 
exposure indicators and exposure conditions. Clinical objective indicators are expressed as continuous 
variables, which can be more conveniently compared to the continuous exposure variables. The drawback 
is that such clinical investigations were only conducted for a fraction of cases (about one third), probably 
the most severe ones, which requested medical attention. A summary of the results obtained is given in 
Table 3a.  
 
Table 3 about here 
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No significant correlation was found between any of the clinical indicators and the assessed doses, which 
seems to exclude any direct dose-response relationships. These results are supported by the lack of 
correlation between the clinical indicators and the amount of product used, which is also an indicator, albeit 
quite rough, of the potential dose. It is interesting to note that the values predicted through modelling 
(concentration, dose) are coherent with the results obtained for a basic parameter (amount of spray used) 
unaffected by the model simplifying hypothesis.  
The relationship found for the maximal concentration and the spraying time is less obvious and must be 
considered in a more detailed way. Weak but significantly positive correlations were found between the 
non-specific inflammatory markers WBC and CRP and the maximal exposure concentrations Cmax. The 
detailed results are presented in table 3 and Figure 8. They show that WBC levels tended to be directly 
correlated with Cmax (LEU = 13.6846 + 0.2926 Cmax, R2=0.15, Pearson = 0.0533, Spearman = 0.0404), 
although no similar trend could be observed for the C-reactive protein levels .  
 
Figure 8  
 
A significant correlation was also found between the spraying time and the pulmonary gas exchange 
marker PaO2 (table 3). Surprisingly, the relationship was positive, i.e. longer spraying times were correlated 
with higher PaO2 (figure 9), i.e. better pulmonary gas exchange, whereas the opposite would have been 
expected. Since the spraying time plays a major role in exposure, this unexpected relationship further 
suggests that no straightforward mechanism exists between the observed health effects and the exposure 
levels to respirable particles. This lack of direct relationship is also apparent when considering the lack of 
correlation between dose vs. PaO2 levels (table 3). The PaO2 levels appears to be highly variable, 
particularly in the lowest dose range.  
 
Figure 9 about here 
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Subcategories regarding smoking history, allergy and asthma or COPD were investigated, to determine 
whether individual susceptibility could explain the occurrence of toxicity features at very low exposure 
levels. No statistically significant differences were found within these subgroups concerning Cmax, Dose, 
and spraying time (Wilcoxon-Mann-Whitney Test) (Table 4). It must however be mentioned that the 
number of cases with objective clinical indicators is reduced, and it is therefore difficult to get clear 
evidence or to analyze subcategories in a consistent way. This is particularly true when considering 
subcategories related to the exposure environment, for which limitations of the two-compartment model 
used to assess doses and concentrations may play a significant role. Compartmental models are known to 
give rough estimates of real exposure conditions. When these models are used to make relative 
comparisons between exposures occurring in the same kind of environment, this drawback is mitigated. 
However, more model limitations are to be expected when comparing exposure conditions of varied nature 
(i.e outdoor v. indoor).  
 
Table 4 about here 
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CONCLUSIONS & RECOMMENDATIONS  
The acute respiratory syndrome associated with the 2002-2003 Swiss outbreak occurred in a wide array of 
exposure conditions, ranging from short to extensive spraying and from poorly ventilated rooms to open 
spaces. The resulting assessed dose and exposure levels obtained were spread on large scales of several 
orders of magnitude. The lack of dose-response correlation with both perceived severity and clinical 
indicators suggests that 1) it is not possible to define a threshold dose below which the incriminated sprays 
could be safely used, and 2) some indirect or complex mechanism(s) predominated in the occurrence of the 
respiratory disease. The occurrence of adverse effects is driven by factors other than the amount of 
respirable particles, such as: metabolic differences, interaction between particles and another chemical 
agent (e.g. residues from the solvent) or even the presence of nanoparticles. The solvent alone could be 
ruled out as the cause of toxicity because the particles reaching the alveoli are essentially made of non-
volatile material (16). It must be pointed out that no environmental factors (heat source due to smoking) were 
found to explain this high response variability and that no correlation was found between the subgroups 
exhibiting individual susceptibility factors (pre-existing lung disease, allergy or smoking) and the exposure 
conditions causing respiratory problems. 
For these reasons and because of the vast array of spraying situations observed, it is unlikely that a simple 
improvement of the exposure conditions may have prevented the occurrence of the toxicity outbreak. Thus, 
enforcing the compliance with the basic safety measures, such as spraying in a well-ventilated space, is 
obviously not sufficient in this case. Besides, commercial products intended for domestic applications must 
be usable without respiratory protective equipment. A more efficient prevention should have taken place 
prior to the product marketing and distribution. It is interesting to note that the product toxicity was tested 
according to German standards prior to marketing. To our knowledge, the effects of 4-5 m aerosol 
droplets were tested on rats at a high exposure concentration. However, tests conduced in such a narrow 
range may not have appropriately reflected the possible human health effects at the pulmonary alveolar 
level. It is well established that the morphological differences between rats and human affect both 
inhalation and deposition patterns. Moreover, retention and clearance patterns have also shown to be 
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species-dependant(25,26). A smaller particle size (around 0.1 m) would have been more appropriate to 
assess alveolar toxicity. Finally, alveolar inflammation and impairment of gas exchange could have taken 
place in rats having inhaled the product, but could have remained undetected if only animal survival was 
considered as an outcome, and if appropriate analyses of lung function and inflammation were not 
performed.  
Additionally, the preventive strategy should take into account the full range of particle size which could be 
generated by various pressurization devices. Hence, the same waterproofing agent can be marketed in 
various mixtures and conditioning for a broad range of applications. A change in the product physico-
chemical properties or in the spraying can design (especially the nebulization system) may have an 
important impact on the distribution of particle size. 
In summary, we believe that new outbreaks of waterproofing spray toxicity may occur if a particular 
combination of fluororesin and triggering factors (solvents, nebulization system) appears in a marketed 
product. The potential toxicity of such a product is likely to remain undetected in the pre-marketing phase if 
new preventive strategies are not applied. Although they may reduce the inhaled dose, written warnings on 
product packages are probably insufficient to prevent the toxicity because of the apparent lack of a safe 
threshold dose. We therefore suggest that: 1) new waterproofing agents should be bench-tested in the final 
mixture in which they are intended to be marketed, 2) a wide range of distribution of particle size should be 
considered for testing in order to encompass interspecies differences as well as the various conditioning in 
which the product is intended to be marketed, and 3) animal toxicity experiments should assess sensitive 
markers of pulmonary function and inflammation. 
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LIST OF SYMBOLS  
C Mass concentration [g/m3] [mg/m3] or [g/m3] 
 C0 incoming conc., CFF far-field conc., CNF  near-field conc. 
E Emission rate [g/s] [mg/s] or [g/s] 
Q Volumic flow [m3/s] 
 Qe inter-compartment flow 
t time [s] 
V  Volume  [m3] 
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TABLES AND FIGURES 
 
 
 
Figure 1. Schematic view of the ventilated chamber . 
 
 
 
E 
C(t), Q
  page 24/37 
   
 
 
 
 
 
 
 
 
 
 
Figure 2. Effective and measured spray emission . 
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Figure 3. Schematic view of the two compartment model surrounding a punctual emission source (the grey 
cube).  
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(a) 
 
 
 
 
 
 
 
 
 
 
 
(b) 
Figure 4. Distribution of the reported exposure time: (a) spraying time, (b) total exposure time in the reported 
cases. The number of corresponding cases is given by y-axis (count) 
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Figure 5. Example of particle size distribution obtained during spraying tests  (*products involved in the toxicity 
outbreak as compared to similar non-toxic products) 
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Ventilation conditions Qe 
(m3/s) 
Air Renewal 
(1/h) 
indoor without ventilation 0.14 1 
indoor with ventilation 0.20 2 
location open on the outside 0.26 3 
outdoor 0.32 - 
 
Table  1. Implementation values for simulation. 
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Figure 6. Typical concentration and dose profile  
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Figure 7. Assessed doses and maximal concentrations expressed in [mg] and [mg/m3] of respirable aerosols  
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 Spearman Correlation Coefficients  (Prob>|r| under H0: Rho=0) 
 Dose Cmax Spraying Time Amount of Product 
DELAY -0.151   ( 0.328 ) -0.175   ( 0.255 ) -0.103    ( 0.475 ) 0.107    ( 0.476 ) 
DYSP. 0.175    ( 0.373 ) 0.261    ( 0.179 ) 0.139    ( 0.448 ) 0.037    ( 0.848 ) 
SCORE 0.216    ( 0.059 ) 0.159    ( 0.168 ) 0.255    ( 0.014 ) 0.288    ( 0.009 ) 
 
 
Table  2. Perceived severity vs. exposure conditions  
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 Correlation Coefficients  (Prob>|r| under H0: Rho=0) 
 Dose Cmax Spraying Time 
Amount of 
Product 
WBC* 0.328   ( 0.102 ) 0.404   ( 0.040 ) 0.079    ( 0.696 ) -0.162    ( 0.439 ) 
CRP* 0.075    ( 0.699 ) 0.375    ( 0.045 ) -0.140    ( 0.445 ) -0.017    ( 0.928 ) 
PO2** 0.021    ( 0.927 ) 0.018    ( 0.938 ) 0.440    ( 0.031 ) 0.389    ( 0.074 ) 
 * = Spearman   * *= Pearson 
   
 
 
Table 3. Correlations between exposure conditions and clinical indicators  
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Table 4. Comparisons between subgroups for smoking habits, asthma or COPD, and allergies  
Mean p-value
yes 0.51
no 0.80
yes 0.26
no 0.55
yes 0.12
no 0.50
yes 4.39
no 4.13
yes 2.65
no 4.53
yes 1.75
no 4.25
yes 11.26
no 12.55
yes 9.87
no 12.07
yes 12.78
no 10.81
Spraying Time
Cmax
Dose
0.45
smoking 
allergy
asthma, COPD
smoking 
allergy
asthma, COPD
smoking 
allergy
asthma, COPD
0.79
0.07
0.49
0.84
0.37
0.74
0.32
0.13
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Figure 8. Relationship between Cmax and indirect inflammatory markers with WBC  
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Figure 9. Relationship between PO2 and spraying time  
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